Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Bosco who wrote (925)	5/22/2000 5:03:00 PM
From: Area51	Read Replies (1) \| Respond to of 1298

Nice mention at streetadvisor.com may explain why it was able to disconnect from ABGX price action for a day: streetadvisor.com Nice article on ABGX to boot: streetadvisor.com Best Regards, Area51

To: Bosco who wrote (925)	5/22/2000 11:39:00 PM
From: david james	Respond to of 1298

Here is some info on the institution that bought 7% of the company first quarter - Dresdner RCM- and is now our leading institution. That puts them ahead of Aventis and Fidelity. I suspect that the recent strength is much more than that little article out today. I believe this is institutional buying - possibly before new coverage. Smart Money ranks the fund #5 of all mutual funds 209.185.191.232 news.morningstar.com Dresdner RCM Biotechnology DRBNX: This fund is suddenly the belle of the ball, thanks to the impressive returns generated by fast-trading manager Faraz Naqvi. The fund is up 349% over the trailing 12 months--trouncing all other biotech funds. Naqvi's portfolio is a mixture of established biotech names such as Biogen and IPOs such as Maxygen MAXY. But investors should approach this fund with caution. Naqvi has only been at the helm since April 1999, and he's had the wind at his back since he started. biz.yahoo.com kiplinger.com Moreover, extraordinary amounts of investment capital are pouring into these companies, even the real wild cards, says Faraz Naqvi, head of Dresdner RCM Biotechnology fund. Naqvi's fund proves that great gains are still possible: Dresdner RCM Biotech led the sector in 1999 with a 111% rise, and it has risen another 56% so far in 2000. Naqvi is partial right now to genomics companies -- firms that map human genes and sell the information and techniques to drug developers. Genomics companies are "picks and shovels" businesses, meaning they supply tools to drug developers. TOP BIOTECH MUTUAL FUNDS stockspecials.com